No Cognitive Benefit for Long-Term Lifestyle Intervention

Share this content:
No Cognitive Benefit for Long-Term Lifestyle Intervention
No Cognitive Benefit for Long-Term Lifestyle Intervention

THURSDAY, Jan. 12, 2017 (HealthDay News) -- For overweight and obese adults with diabetes mellitus, a long-term intensive lifestyle intervention does not offer cognitive benefits, according to a study published online Jan. 9 in the Journal of the American Geriatrics Society.

Stephen R. Rapp, Ph.D., from Wake Forest University in Winston-Salem, N.C., and colleagues examined whether 10 years of lifestyle intervention to induce and maintain weight loss could improve cognitive function. Data were obtained for 3,751 overweight and obese individuals aged 45 to 76 years with type 2 diabetes mellitus who were randomized to intensive lifestyle intervention for weight loss through reduced caloric intake and increased physical activity or a control condition of diabetes support and education (DSE).

The researchers observed no significant difference in overall or domain-specific cognitive function for assignment to the lifestyle intervention or DSE. Across prespecified groups, the results were fairly consistent; there was some evidence of trends for differential intervention effects, with modest harm from intensive lifestyle intervention in participants with greater body mass index and those with a history of cardiovascular disease. There was no correlation for cognitive function with changes in weight or fitness.

"A long-term behavioral weight loss intervention for overweight and obese adults with diabetes mellitus was not associated with cognitive benefit," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »